Andrea Spica was initially diagnosed with essential thrombocythemia (ET) in the late 1990s and, approximately 10 years later, her condition evolved into myelofibrosis (MF). Originally, she sought treatment from a local hematologist, but once her disease progressed, she was referred to The University of Texas MD Anderson Cancer Center. She is a big proponent of clinical trials as a treatment alternative, and she has been engaged in several over the course of her treatment journey. Today, Andrea collaborates closely with her healthcare team on her therapy options for the future. She lives in Dallas, Texas where she also runs a support group for patients and caregivers living with myeloproliferative neoplasms (MPNs).